tiragolumab + atezolizumab + capecitabine + oxaliplatin

This is a **combination therapy** consisting of **tiragolumab**, **atezolizumab**, **capecitabine**, and **oxaliplatin**. Tiragolumab is a monoclonal antibody targeting TIGIT (T-cell immunoreceptor with Ig and ITIM domains), acting as an immune checkpoint inhibitor to enhance T-cell mediated antitumor activity[1][5]. Atezolizumab is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), another immune checkpoint protein, blocking its interaction with PD-1 and B7.1 to restore antitumor immune responses[1][5]. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), a cytotoxic antimetabolite that inhibits thymidylate synthase, impeding DNA synthesis in tumor cells. Oxaliplatin is a third-generation platinum-based chemotherapeutic that induces cross-linking of DNA, leading to cell cycle arrest and apoptosis. This combination is under investigation for the treatment of advanced/metastatic solid tumors, leveraging checkpoint inhibition and cytotoxic chemotherapy.